Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes

Abstract

Medical providers significantly overestimated the incidence of acute vomiting by 20% and 18% in HEC and MEC patients, respectively. While they correctly estimated the rate of delayed vomiting in HEC patients, they underestimated it by 16% in MEC patients. With respect to nausea, medical providers correctly estimated rates of both acute and delayed nausea in HEC patients, but significantly underestimated rates of acute and delayed nausea by 16% and 30%, respectively, in MEC patients.

Role of Psychosocial Variables on Chemotherapy-Induced Nausea and Vomiting and Health-Related Quality of Life among Cancer Patients: A European Study

“…This was particularly evident for those suffering from delayed nausea. These aspects confirm that, although health care professionals tend to pay more attention to vomiting than nausea, the latter is also extremely negative for patients who undergo chemotherapy [6,7] .…”

“…Nausea is, from the patients' own perspective, even more negative than vomiting, while, in contrast, medical providers tend to consider their patients' vomiting worse than nausea, with the risk to underestimate the latter [6,7] . CINV has extremely negative consequences by reducing daily functioning and quality of life (QoL) [8][9][10][11][12] .…”

Parents' and Health-Care Providers' Perspectives on Side-Effects of Childhood Cancer Treatment in Indonesia

“…Our findings are in harmony with earlier adult cancer studies, revealing that overall agreement between cancer patients and medical professionals was rather poor while agreement between nurses and doctors was more considerable (Liau et al, 2005;Mulders et al, 2008;Sikorskii et al, 2012).…”

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

“…Although the significance of chemotherapy-induced nausea and vomiting has not been questioned, successful development of antiemetics during the last 25 years can lead to the assumption that this is no longer a major problem. However, numerous patient surveys have now demonstrated that chemotherapy-induced nausea and vomiting continues to exist, particularly during the delayed period and particularly in patients receiving moderately emetogenic chemotherapy such as cyclophosphamide/doxorubicin, and that the incidence of this problem in the delayed period is markedly underestimated by healthcare professionals [7,10,15,23]. Second, it is necessary to have appropriate remedies to address the problem.…”